SCHEMBL3703540

SCHEMBL3703540

COc1ccc(Cn2cnc3c(NC(C)c4cc5cccc(Cl)c5c(CCN5CCOCC5)n4)ncnc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 5/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
YTHDC1 Q96MU7 2/20 0.38
HPGD P15428 1/20 0.37
SRC P12931 3/20 0.37
KDR P35968 2/20 0.37
PIK3CD O00329 1/20 0.36
PIK3R2 O00459 1/20 0.36
INSR P06213 1/20 0.36
ALK Q9UM73 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FLT3 P36888 1/20 0.36
PDGFRA P16234 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3703537 1.00 PDE10A (0.40) PDE10AHDAC1HDAC6YTHDC1HPGD
SCHEMBL3699067 0.94 PDE10A (0.41) PDE10AHDAC1HDAC6YTHDC1HPGD
SCHEMBL3699064 0.94 PDE10A (0.41) PDE10AHDAC1HDAC6YTHDC1HPGD
SCHEMBL3699662 0.87 HDAC1 (0.42) PDE10AHDAC1HDAC6YTHDC1HPGD
SCHEMBL3699660 0.87 HDAC1 (0.42) PDE10AHDAC1HDAC6YTHDC1HPGD
SCHEMBL4569344 0.86 HDAC1 (0.38) PDE10AHDAC1HDAC6YTHDC1HPGD
SCHEMBL4530549 0.86 ALDH1A1 (0.41) PDE10AHDAC1HDAC6HPGDALDH1A1
SCHEMBL4569306 0.85 HDAC1 (0.43) PDE10AHDAC1HDAC6YTHDC1HPGD
SCHEMBL3702155 0.84 HDAC1 (0.46) HDAC1HDAC6YTHDC1HPGDKDM4E
SCHEMBL3702160 0.84 HDAC1 (0.46) HDAC1HDAC6YTHDC1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388183-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2016-07-12 US disclosed
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2015-01-29 US disclosed
US-8901133-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031672-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PDE10A 455/4885HDAC1 440/4885HDAC6 340/4885
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PDE10A 455/4885HDAC1 440/4885HDAC6 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.